IRIS
CELLERINO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.251
AS - Asia 36
NA - Nord America 6
SA - Sud America 1
Totale 4.294
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.249
CN - Cina 30
US - Stati Uniti d'America 5
SG - Singapore 4
VN - Vietnam 2
BR - Brasile 1
CA - Canada 1
FI - Finlandia 1
GB - Regno Unito 1
Totale 4.294
Salva come PNG Salva come JPEG
Città #
Genoa 2.322
Genova 911
Vado Ligure 615
Rapallo 389
Beijing 16
Bordighera 11
Singapore 4
Ashburn 3
Boardman 2
Can Tho 2
City of London 1
Curitiba 1
Lappeenranta 1
Toronto 1
Totale 4.279
Salva come PNG Salva come JPEG
Nome #
Different MRI patterns in MS worsening after stopping fingolimod 171
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 169
Levodopa-induced neutropenia. 159
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? 150
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 150
A novel prion protein gene-truncating mutation causing autonomic neuropathy and diarrhea 149
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 132
Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study 121
Homonymous hemianopia as the first sign of posterior cortical atrophy 117
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 109
Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients 104
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 102
Assessing upper limb function in Multiple Sclerosis by an engineered glove 100
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 97
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 93
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 93
Multiscale networks in multiple sclerosis 88
Corneal sub-basal nerve plexus analysis in patients with multiple sclerosis 86
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study 85
Clinical and radiological correlates of apathy in multiple sclerosis 82
Neuroaxonal Degeneration in Patients With Multiple Sclerosis: An Optical Coherence Tomography and in Vivo Corneal Confocal Microscopy Study 82
Risk of Persistent Disability in Patients with Pediatric-Onset Multiple Sclerosis 77
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 74
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 72
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 72
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 67
Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal 67
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 67
Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study 67
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions 65
On the Assessment of Gray Code Kernels for Motion Characterization in People with Multiple Sclerosis: A Preliminary Study 65
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 62
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 62
The effect of Cladribine and Fingolimod treatments on retinal atrophy 60
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 60
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 60
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 56
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 54
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial 50
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 49
The role of disconnection in explaining disability in multiple sclerosis 46
What happens after fingolimod discontinuation? A multicentre real-life experience 44
Erratum: Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study 42
Predicting disease severity in Multiple Sclerosis using multimodal data and machine learning 42
EXPLORING THE INTERACTION BETWEEN FOCAL INFLAMMATION AND AXONAL INJURY IN MULTIPLE SCELROSIS: A NEW MECHANISM-DRIVEN FRAMEWORK TO MONITOR DISEASE ACTIVITY AND PROGRESSION 41
Lesion phenotyping based on magnetic susceptibility in pediatric multiple sclerosis 39
Physical exercise moderates the effects of disability on depression in people with multiple sclerosis during the covid-19 outbreak 38
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series 38
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 37
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience 36
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 36
ELEVATED RISK OF THROMBOTIC MANIFESTATIONS OF SARS-COV-2 INFECTION IN CANCER PATIENTS: A LITERATURE REVIEW 34
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 34
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 33
Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores 32
Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study 27
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis 25
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 23
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 22
Markerless Video-based Gait Analysis in People with Multiple Sclerosis 21
null 20
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 19
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis 18
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 17
Relationship between ovarian reserve and disease activity in women with multiple sclerosis 15
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 10
Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study 6
Totale 4.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.493
article - articoli 18.646
book - libri 0
conference - conferenze 460
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 194
Totale 38.793
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 36 24 20 11 18 18 36 7 10
2021/2022253 9 4 5 21 13 19 4 55 24 41 9 49
2022/2023469 34 44 11 51 52 62 4 33 77 4 77 20
2023/2024556 20 42 16 58 34 66 156 24 24 26 30 60
2024/20251.582 87 105 64 102 208 163 159 259 95 72 137 131
2025/2026853 339 136 188 190 0 0 0 0 0 0 0 0
Totale 4.440